Mercados españoles cerrados

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
3,90000,0000 (0,00%)
Al cierre: 04:00PM EDT
3,9000 0,00 (0,00%)
Después del cierre: 04:00PM EDT

Alimera Sciences, Inc.

6310 Town Square
Suite 400
Alpharetta, GA 30005
United States
678 990 5740
https://alimerasciences.com

Sector(es)Healthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo154

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Richard S. Eiswirth Jr.CEO & Director597,87kN/A1968
Mr. David R. HollandCo-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets413,5kN/A1964
Dr. Philip Ashman Ph.D.President of International Operations389,86kN/A1965
Mr. Todd Michael WoodPresident of U.S. OperationsN/AN/A1970
Mr. Elliot Maltz CPACFO & TreasurerN/AN/A1985
Mr. Jason WernerChief Operating OfficerN/AN/AN/A
Christopher S. VisickVP, General Counsel & SecretaryN/AN/AN/A
Dr. David Dyer M.D.Chief Retina SpecialistN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Gobierno corporativo

El ISS Governance QualityScore de Alimera Sciences, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.